Literature DB >> 349395

Prognostic factors for patients with brain tumors.

E A Gehan, M D Walker.   

Abstract

Patient characteristics of 225 patients entered into a clinical trial conducted by the Brain Tumor Study Group (69-01) were examined for their relationship to survival time. In the clinical study, all patients received surgery and were randomized to control treatment (no further treatment), X-ray therapy (XRT), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), or BCNU + XRT. When treatment was considered as a possible prognostic factor, the patient characteristics most related to survival were: XRT (receiving XRT favorable), age (young, favorable), symptoms of seizures and cranial nerves (both favorable), BCNU treatment (yes, favorable), encapsulated tumor (yes, favorable), and parietal tumor (no, favorable). When treatment was not considered a possible prognostic factor, the patient characteristics most related to survival were: age (young, favorable), biopsy (operation biopsy only, unfavorable), seizures (yes, favorable), cranial nerve symptoms (yes, favorable), and parietal location of tumor (yes, unfavorable). Knowledge of prognostic factors can be used for stratifying patients in clinical studies, for testing the comparability of groups of patients, and in the analysis of the results of clinical studies.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 349395

Source DB:  PubMed          Journal:  Natl Cancer Inst Monogr        ISSN: 0083-1921


  19 in total

1.  Prognostic significance of preoperative MRI scans in glioblastoma multiforme.

Authors:  M A Hammoud; R Sawaya; W Shi; P F Thall; N E Leeds
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

2.  The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.

Authors:  Meral Y Sayin; Bektas Kaya; Bekir H Bakkal; Kadri Altundag; Muzaffer B Altundag
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; D F Nelson; A J Fischbach; C H Chang; M Rotman; S O Asbell
Journal:  J Neurooncol       Date:  1992-03       Impact factor: 4.130

4.  Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy.

Authors:  K L Chow; Y P Gobin; T Cloughesy; J W Sayre; J P Villablanca; F Viñuela
Journal:  AJNR Am J Neuroradiol       Date:  2000-03       Impact factor: 3.825

5.  Pathology of human malignant gliomas after radiation and chemotherapy.

Authors:  D Schiffer; M T Giordana; P Paoletti; R Soffietti; L Tarenzi
Journal:  Acta Neurochir (Wien)       Date:  1980       Impact factor: 2.216

6.  Prognostic factors for high-grade malignant glioma: development of a prognostic index. A Report of the Medical Research Council Brain Tumour Working Party.

Authors: 
Journal:  J Neurooncol       Date:  1990-08       Impact factor: 4.130

Review 7.  Tumoral invasion in the central nervous system.

Authors:  Y A De Clerck; H Shimada; I Gonzalez-Gomez; C Raffel
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 8.  Fast neutron therapy for malignant astrocytomas. A review.

Authors:  P D Kurup; T F Pajak; J S Nelson; J Mansell; F R Hendrickson; L Cohen; T W Griffin
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

9.  Multivariate analysis of factors affecting postoperative survival in malignant astrocytoma. Importance of DNA quantification.

Authors:  K Hirakawa; K Suzuki; S Ueda; Y Nakagawa; E Yoshino; N Ibayashi; K Hayashi
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

10.  The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models.

Authors:  Georgios Iliadis; Panagiotis Selviaridis; Anna Kalogera-Fountzila; Anna Fragkoulidi; Dimos Baltas; Nikolaos Tselis; Athanasios Chatzisotiriou; Despina Misailidou; Nikolaos Zamboglou; George Fountzilas
Journal:  Strahlenther Onkol       Date:  2009-11-10       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.